reason report
remov gantenerumab valu aducanumab fail pt
bottom line remov morphosys/roch gantenerumab
phase anti-beta amyloid alzheim diseas morphosi
valuat yesterday announc aducanumab phase
trial failur drug target brain protein similar
molecular featur gantenerumab similar aducanumab
four fail beta-amyloid antibodi studi date roch
announc chang on-going gantenerumab phase
trial time longer sound basi support
potenti posit outcom believ assign valu
asset morphosi previous valu morphosi ownership
gantenerumab royalti remov lower price target
us adr princip valu driver mor
remain proprietari antibodi non-hodgkin lymphoma nhl
royalti jnj op rapidli grow antibodi
psoriasi tremfya continu rate mor outperform ahead
import year final step develop
gantenerumab previous repres price
target part morphosi initi januari valu
gantenerumab add-on cash flow base valu
accord similar alzheim diseas program deriv
valu anti-amyloid program phase use three separ
compani financ royalti transact two drug serv
compar see note mor pretti face
offer high valu futur top royalti base drug
sinc fail phase trial failur suggest
also remov valu gantenerumab royalti
chang mor estim previous top-sid
gantenerumab valu per share valu mor explicitli
model futur royalti incom chang revenu
earn estim mor gantenerumab develop fulli
fund roch decis compani cancel phase
develop would also impact morphosi
dcf analysi discount rate
year price history/av daili volume mil mor gy
compani inform svb leerink llc research
revenu mm
pleas refer page import disclosur price chart analyst certif
price target morphosi mor us adr rate stock
outperform morphosi german biopharmaceut compani long legaci innov
therapeut monoclon antibodi discoveri develop histor morphosi taken
care path build broad portfolio skinni collabor bigger biopharma
compani result potenti low-to-mid singl digit royalti product
collabor final come fruition first reach market
tremfya begin gener royalti morphosi larger basi
compani valu howev morphosi wholly-own
hematolog malign shown impress data single-arm phase ii trial
patient transplant-inelig relaps refractori dlbcl endors
us fda data appear suffici acceler approv
abl gener revenu rang mid still potenti
develop larger popul sever differ form nhl import
asset mor stock royalti jnj antibodi psoriasi estim
worth today could increas substanti revenu exce perform
product indic royalty-bear product agreement contribut anoth
compani outstand cash reserv add anoth give total
price target mor base dcf methodolog cash flow
termin growth driver forecast royalti tremfya risk-adjust
sale risk-adjust royalti assum discount rate
base compani wacc addit factor mor cash balanc valuat
risk view outlook valuat morphosi includ failur obtain approv
either us ex-u jurisdict base l-mind forecast
product also subject risk better-than-expect market share gain competit
brand product roch polatuzumab lack willing physician
patient chang new treatment long-stand treatment option
payer us europ could also refus reimburs expens combin
plu revlimid could potenti cost year treatment
addit morphosi current sole sourc incom royalti tremfya could lower
expect due chang highli competit immunolog treatment market risk
morphosi includ develop regulatori disappoint partner out-
licens antibodi two product fail compani valuat would reduc
approxim
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view event
possibl intern confer
collabor annouc
partnership ex us right
million
royalti mileston po adjust
svb leerink llc research compani file
million
sale
 total revenu
sg total revenu
svb leerink llc research compani file
mm
pv flow
equiti
debt
